Yazar "Neven, P." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes(Churchill Livingstone, 2023) Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C. S.[Abstract Not Available]Öğe Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer(E M H Swiss Medical Publishers Ltd, 2022) Paluch-Shimon, S.; Neven, P.; Cicin, I.; Jiang, Z.; Goetz, M. P.; Shimizu, C.; Huang, C. -S.[Abstract Not Available]Öğe Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer(Elsevier, 2022) Paluch-Shimon, S.; Neven, P.; Huober, J.; Cicin, I.; Jiang, Z.; Goetz, M. P.; Shimizu, C.[Abstract Not Available]
